Combination of pembrolizumab and lenvatinib in syngeneic murine models led to activation of CD8+ T cells through reduction of TAMs, which are immune regulators in the TME, and to activation of the interferon pathway that resulted in a synergistic effect with greater reduction in tumor volume and higher response rate [54,55]. Here, CD8A is linked to neoplasm.